Best of 2019 - Upadacitinib (RINVOQ) FDA Approved for Rheumatoid Arthritis

Save

The US Food and Drug Administration (FDA) on Friday, August 16, approved AbbVie JAK1 inhibitor, Rinvoq (upadacitinib) for adults with  rheumatoid arthritis with moderately to severely active disease either not responding to, or intolerant of, methotrexate (MTX). 

Gilead Submits Filgotinib NDA to the FDA

Save

Gilead has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis (RA).

Upadacitinib Effective in Ankylosing Spondylitis

Save

Lancet reports that the selective JAK1 inhibitor, upadacitinib, was effective when given to patients with active ankylosing spondylitis.

Is Anifrolumab Good Enough for Systemic Lupus Erythematosus?

Save

The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.

RheumNow Podcast - The Elusive Hand OA Problem (12.13.19)

Save

Dr. Jack Cush recaps the news and journal reports from the past week on RheumNow.com.

Variations in First Biologic Use in Rheumatoid Arthritis

Save

A Canadian analysis shows that rheumatoid arthritis (RA) patients are more likely to receive biologic DMARDs earlier if they are younger, female, and living in urban areas closer to prescribers.

Biologic Safety Guidelines from the British Society for Rheumatology

Save

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis.

Secukinumab Improves Enthesitis

Save

Secukinumabs (SEC) effect on enthesitis in psoriatic arthritis (PsA) was studied in the FUTURE 2 and 3 studies and SEC was shown significantly reduced enthesitis by more than 65% within 14 week. 

IL-17 Inhibitors In Non-Radiographic Axial SpA

Save

This meeting sees new data on using anti-IL-17 agents in non-radiographic axial SpA. Up until now these patients have only had TNF inhibitors available, so data about the efficacy of IL17 inhibitors is really important.

BMS and Celgene Merge as Amgen Buys Otezla

Save

Bristol-Myers Squibb (BMS) has completed its $74 billion acquisition of Celgene. With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Save

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Save

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

ACR 2019 - Report From Day 3 (Tuesday)

Save

Here's my summary of key studies presented Tuesday. 

Tofacitinib in Polyarticular JIA

Psoriatic Arthritis at ACR 2019

Save

Below are several of the highlight studies in psoriatic arthritis (PsA) presented at the ACR 2019 annual meeting in Atlanta. 

ACR 2019 – Best of the Plenary Sessions

Save

The ACR Plenary Sessions featured some of the best research presented on Sunday, Monday, and Tuesday in Atlanta. Here are my seven notable highlights from the Plenaries.

ACR 2019 - Report from Day One (Sunday)

Save

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis

New Treatments in Axial SpA from #ACR2019

Save

There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.

RheumNow Podcast – ACR 2019 Round Up (11.15.19)

Save

Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.

RheumNow Podcast – Better Ways to Treat Gout (11.8.19)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.